Literature DB >> 8946150

The clinical implications of impaired glucose tolerance.

K G Alberti1.   

Abstract

Impaired glucose tolerance (IGT) was introduced in 1979 as an intermediate category covering the grey area between unequivocal diabetes mellitus and risk free more normal glucose tolerance. The IGT group included those at high risk of subsequent development of non-insulin-dependent diabetes mellitus (NIDDM) but low risk of specific diabetic complications. Categorisation of subjects as IGT is hampered by the variability of the oral glucose tolerance test, but even those shown to be IGT only once are at increased risk of developing NIDDM. The relative roles of inheritance, fetal undernutrition, and environmental life style factors (physical inactivity and diet) in the aetiology and pathogenesis of IGT are discussed, with all contributing. The prevalence of IGT in different populations has now been widely studied with values ranging from 2 to 25% in adults. Rates of progression to NIDDM also vary widely from 2 to 14% per year. Risk factors for progression are discussed. IGT also carries an increased risk of development of cardiovascular disease (CVD) and forms part of the "metabolic syndrome". The role of insulin resistance as a common aetiological factor is briefly reviewed. Finally, possible means of treatment of IGT are listed with the intent of delaying the onset of diabetes and CVD, which is of obvious clinical importance.

Entities:  

Mesh:

Year:  1996        PMID: 8946150     DOI: 10.1002/(SICI)1096-9136(199611)13:11<927::AID-DIA279>3.0.CO;2-E

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  16 in total

Review 1.  What should we measure in the diabetic patient and how does this respond to therapy?

Authors:  Desmond G Johnston; Stephen Robinson; Shareen Forbes
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

2.  Strategies for preventing type 2 diabetes: an update for clinicians.

Authors:  Kaivan Khavandi; Halima Amer; Bashar Ibrahim; Jack Brownrigg
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

Review 3.  Best practice in primary care pathology: review 10.

Authors:  W S A Smellie; N Shaw; R Bowley; M F Stewart; A M Kelly; P J Twomey; P R Chadwick; J B Houghton; J P Ng; A J McCulloch
Journal:  J Clin Pathol       Date:  2007-05-11       Impact factor: 3.411

Review 4.  A risk-benefit assessment of metformin in type 2 diabetes mellitus.

Authors:  H C Howlett; C J Bailey
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

5.  The impact of diabetes on workforce participation: results from a national household sample.

Authors:  Sandeep Vijan; Rodney A Hayward; Kenneth M Langa
Journal:  Health Serv Res       Date:  2004-12       Impact factor: 3.402

Review 6.  Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease.

Authors:  P Palatini
Journal:  Curr Hypertens Rep       Date:  2001-09       Impact factor: 5.369

7.  Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus.

Authors:  Yi-Jen Hung; Shi-Wen Kuo; Chao-Hung Wang; Hung-Yu Chang; Sheng-Hwu Hsieh; Harald Landen
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 8.  Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

Authors:  André J Scheen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Beyond the brain: disrupted in schizophrenia 1 regulates pancreatic β-cell function via glycogen synthase kinase-3β.

Authors:  Agata Jurczyk; Anetta Nowosielska; Natalia Przewozniak; Ken-Edwin Aryee; Philip DiIorio; David Blodgett; Chaoxing Yang; Martha Campbell-Thompson; Mark Atkinson; Leonard Shultz; Ann Rittenhouse; David Harlan; Dale Greiner; Rita Bortell
Journal:  FASEB J       Date:  2015-11-06       Impact factor: 5.191

10.  Assessing impaired fasting blood glucose criteria for high-risk dysglycaemic populations: an experience from a European population state.

Authors:  Sarah Cuschieri; Stephan Grech
Journal:  J Diabetes Metab Disord       Date:  2020-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.